SCHEMBL5710098

SCHEMBL5710098

COc1ccc(B(O)c2ccc(OC)cc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 5/20 0.73
CA2 P00918 5/20 0.73
ENPP2 Q13822 2/20 0.73
CA7 P43166 2/20 0.58
CA9 Q16790 2/20 0.58
CA12 O43570 1/20 0.58
CA14 Q9ULX7 1/20 0.58
ORAI1 Q96D31 4/20 0.52
ORAI2 Q96SN7 4/20 0.52
ORAI3 Q9BRQ5 4/20 0.52
TRPV6 Q9H1D0 4/20 0.52
PCSK9 Q8NBP7 1/20 0.50
ACHE P22303 1/20 0.48
LTA4H P09960 1/20 0.46
ESR2 Q92731 1/20 0.46
CES2 O00748 1/20 0.46
CES1 P23141 1/20 0.46
TDP1 Q9NUW8 3/20 0.46
MAPK1 P28482 2/20 0.46
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16653533 0.85 CA1 (0.67) CA1CA2ENPP2CA7CA9
SCHEMBL4673 0.84 CA2 (1.00) CA1CA2ENPP2CA7CA9
SCHEMBL28331836 0.82 CA2 (0.95) CA1CA2ENPP2CA7CA9
SCHEMBL26048241 0.82 CA1 (0.70) CA1CA2ENPP2CA7CA9
SCHEMBL3737373 0.80 CA1 (0.67) CA1CA2ENPP2CA7CA9
SCHEMBL13686655 0.80 CA1 (0.67) CA1CA2ENPP2CA7CA9
SCHEMBL12270719 0.78 ORAI1 (0.52) CA1CA2ENPP2ORAI1ORAI2
SCHEMBL28832985 0.78 CA2 (0.86) CA1CA2ENPP2CA7CA9
SCHEMBL257917 0.78 CA2 (0.86) CA1CA2ENPP2CA7CA9
SCHEMBL5836185 0.78 CA2 (0.86) CA1CA2ENPP2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6600066-B1 Process for preparing perhalogenated monoorganoboranes or diorganoboranes which makes it possible to obtain these compounds under conditions which can readily be implemented in the industry is described. BASELL POLYOLEFINE GMBH (DE) 2003-07-29 US claimed
EP-1140947-B1 METHOD FOR PRODUCING MONO-ORGANOBORANES OR DI-ORGANOBORANES BASELL POLYOLEFINE GMBH (DE) 2003-03-12 EP claimed
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME NIPPON SHOKUBAI CO., LTD. (JP) 2026-02-19 US disclosed
EP-2886548-A1 METHOD FOR PRODUCING BORINIC ACID DERIVATIVE, AND NOVEL BORINIC ACID DERIVATIVE Manac Inc. (JP) 2015-06-24 EP disclosed
US-20150105562-A1 METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES MANAC INC. (JP) 2015-04-16 US disclosed
EP-1732896-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) Aventis Pharmaceuticals Inc. (US) 2006-12-20 EP disclosed
EP-1339725-B1 DNA METHYL TRANSFERASE INHIBITORS PENN STATE RES FOUND (US) 2006-11-22 EP disclosed
WO-2005097750-A1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMACEUTICALS INC. (US) 2005-10-20 WO disclosed
US-20050227933-A1 Treatment of bacterial induced diseases using DNA methyl transferase inhibitors BENKOVIC STEPHEN J 2005-10-13 US disclosed
EP-1339725-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2003-09-03 EP disclosed
US-6600066-B1 Process for preparing perhalogenated monoorganoboranes or diorganoboranes which makes it possible to obtain these compounds under conditions which can readily be implemented in the industry is described. BASELL POLYOLEFINE GMBH (DE) 2003-07-29 US disclosed
EP-1140947-B1 METHOD FOR PRODUCING MONO-ORGANOBORANES OR DI-ORGANOBORANES BASELL POLYOLEFINE GMBH (DE) 2003-03-12 EP disclosed
EP-1003753-B1 COMPOUNDS CONTAINING BORON AND ALUMINIUM BASELL POLYOLEFINE GMBH (DE) 2003-03-05 EP disclosed
US-6417302-B1 REACTION PRODUCT OF DI(PENTAFLUOROPHENYL) BORINIC ACID AND ORGANOALUMINUM COMPOUND; OLEFIN POLYMERIZATION COORDINATION CATALYSTS BASELL POLYOLEFINE GMBH (DE) 2002-07-09 US disclosed
WO-2002044184-A2 DNA METHYL TRANSFERASE INHIBITORS THE PENN STATE RESEARCH FOUNDATION (US) 2002-06-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150105562-A1 METHOD FOR PREPARING BORINIC ACID DERIVATIVES AND NOVEL BORINIC ACID DERIVATIVES ADORA2B, TPSAB1, ACVR2B CA1 357/4885CA2 259/4885ENPP2 116/4885
US-20260050210-A1 RESIST COMPOSITION AND METHOD FOR PRODUCING SAME MAL2, MCM6, MCM3 CA1 1842/4885CA2 1817/4885ENPP2 4133/4885
US-20050227933-A1 Treatment of bacterial induced diseases using DNA methyl transferase inhibitors DNMT1, TPMT, GNMT CA1 3630/4885CA2 3114/4885ENPP2 681/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.